Compare Illumina, Inc. (ILMN) vs Lionsgate Studios Corp Common Shares (LION) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Lionsgate Studios Corp Common Shares — how do they compare? Illumina, Inc. trades at $271.84 (market cap $40.95B), while Lionsgate Studios Corp Common Shares trades at $10.86 (market cap $3.31B). The key difference: Illumina, Inc. is far larger — about 12.4× Lionsgate Studios Corp Common Shares's market cap, and Illumina, Inc. is trading nearer its 52-week high, Lionsgate Studios Corp Common Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 84 Days and Lionsgate Studios Corp Common Shares for 0 Days on average.
| ILMN | LION | |
|---|---|---|
Market Cap | $40.95B | $3.31B |
Volume | 1,893,606 | 2,146,134 |
Sector | Health | Technology |
52-Week High | $293.69 | $16.40 |
52-Week Low | $93.00 | $5.91 |
Typical Hold Time | 84 Days | 0 Days |
Enterprise Value | $42.31B | $6.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.76, down 1.77% today but near its 52-week high of $278.99. The stock has surged 94.9% YTD, supported by strong earnings beats and positive technical momentum. Recent quarterly results exceeded expectations with Q2 2026 EPS of $1.31 beating the $1.23 estimate. The company shows improving fundamentals with 2025 net income of $850 million and robust operating cash flow of $1.08 billion.
ILMN presents growth potential through AI integration and S&P 500 inclusion, but faces risks from China headwinds and elevated valuations. Analyst consensus remains bullish with 54% buy ratings, though the $241 consensus price target suggests limited upside. Key catalysts include continued sequencing growth and margin expansion, while competition and cost volatility remain concerns.
LION trades at $11.12, up 0.36% on the day, with a market cap of approximately $1.3 billion. The stock shows mixed signals: strong analyst support (87.5% buy rating) and a consensus price target of $16.80 suggest upside, but negative net income and shareholder equity highlight financial strain. Recent Q1 2027 earnings beat estimates with EPS of $0.37, yet the company remains unprofitable with a net loss of $128.5 million in 2025. Takeover interest from firms like Bolloré adds speculative appeal.
The outlook hinges on operational turnaround and potential M&A. Revenue growth from hit films like 'Michael' and a valuable content library offer catalysts, but high debt ($3.65B total) and consistent losses pose significant risks. Investors should weigh the 51% upside to price targets against fundamental weaknesses and industry volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Lionsgate Studios Corp Common Shares
Lionsgate Studios Corp. is a standalone content company that develops, finances, produces, and distributes motion pictures and television series, licensing its content to theaters, streaming platforms, television networks, and home entertainment channels.
Read more on LION →
